Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Phase 1LYMPHIRPembrolizumabPositive

AI Analysis

Summary

Citius Oncology highlighted Phase 1 data from an investigator-initiated study of LYMPHIR in combination with pembrolizumab for treatment of recurrent or refractory gynecologic malignancies.

Clinical Trial Data

Phase

Phase 1

Importance:5/10

Sentiment:

0.50

oncologyphase_1_datacombination_therapygynecologic_malignanciesinvestigator_initiated_study

Related Companies

$CTXR

Read the original article

Published by yahoo_finance on June 1, 2026 11:00 AM

Read Original